A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Trial details
- Registry ID
- NCT06018428
- Drugs studied
- bempikibart (ADX-914)
TrialRedline tracks 2 clinical trials sponsored by Q32 Bio Inc.: 2 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)NCT06018428 | bempikibart (ADX-914) | Active not recruiting | 2026-06Estimated |
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)NCT05509023 | ADX-914 | Active not recruiting | 2024-12Estimated |
Names as written in the registry records.